Spark Time!
Episodes
Ep. 33 How Lytix Biopharma Reimagined Host-Defense Peptides as Oncolytic Molecules for Immunotherapy
06 Jan 2026
Contributed by Lukas
In this episode of Spark Time!, we speak with Øystein Rekdal, co-founder and CEO of Lytix Biopharma, about how the company reimagined host-defense pe...
Ep. 32 Alzheimer's Breakthrough? Recall Thinks Restoration Is Possible
02 Dec 2025
Contributed by Lukas
What if an Alzheimer’s therapy did not just slow decline, but restored memory and physical health back to baseline?In this episode of Spark Time, we...
Ep. 31 Zero G, Crystals and Keytruda: Space MD Builds the New Frontier of Drug Design
07 Nov 2025
Contributed by Lukas
In this episode, we have a, high-energy conversation with Molly Mulligan and Ken Savin from Space MD about how space-made crystals are changing drug d...
Ep. 30 The Tiny Cargo Company's Milk Exosomes Could Shape the Future of Oral GLP-1 Delivery
09 Oct 2025
Contributed by Lukas
We talk with Alan Gourdie and Spencer Marsh from The Tiny Cargo Company, the team commercializing one of nature’s most elegant delivery systems, mil...
Ep. 29 Christian Kersten & Marte Cameron: From Serendipitous Discovery to a New Era in Chronic Pain Treatment
03 Sep 2025
Contributed by Lukas
Neuropathic pain affects nearly 10% of the global population, yet effective treatments remain elusive. In this episode of Spark Time, we sit down with...
Ep. 28 Aneil Mallavarapu on Building and Monetizing TechBio Platforms, Storytelling and Why Diagnostics Won't Save a System Designed to Fail
26 Jul 2025
Contributed by Lukas
In this expansive episode, Aneil Mallavarapu delivers a masterclass on what TechBio is really about and why most investors and founders are still gett...
Ep. 27 Burn the CRO Playbook: Ardian Latifi on Building a Sponsor-First Model
29 Jun 2025
Contributed by Lukas
Learn how flexibility, real-time control, and localized trial expertise are reshaping the future of CRO's from the man redefining it. Listen in as A...
Ep. 26 The Australian Advantage; How Global Biotechs Are Accelerating R&D with Agilex Biolabs
05 Jun 2025
Contributed by Lukas
In this episode of Spark Time, we sit down with Steve McIntyre, CEO of Agilex Biolabs, Cameron Smith, Chief Business Development Officer, Agilex Biola...
Ep. 25 Javier Tordable Saw Biotech's Blind Spot. Then Built a Company to Fix It.
02 May 2025
Contributed by Lukas
What does a former Google leader see when he looks at the drug discovery process? A broken system and a once-in-a-generation opportunity to rebuild it...
Ep. 24 AI vs. Clinical Trial Chaos: Maree Beare Isn't Waiting Around
21 Apr 2025
Contributed by Lukas
We sit down with Maree Beare, the visionary CEO and founder of Clinials. Maree shares her journey in transforming clinical trials through AI-driven so...
Ep. 23 Jason Foster on Scaling Indivior, Leading Ori Biotech, and Solving the Real-World Bottlenecks Holding Back Cell and Gene Therapy
06 Apr 2025
Contributed by Lukas
This week we are joined by Jason Foster, CEO of Ori Biotech to talk about the future of CGT and why scalable strategic manufacturing is in a make or b...
Ep. 22 Audrey Greenberg on Strategically Enabling Cell & Gene Therapy
09 Mar 2025
Contributed by Lukas
In this episode, we sit down with Audrey Greenberg, Founder and CEO of AG Capital Advisors, to explore her journey building and scaling the Center for...
Ep. 21 Emily Fang on Authentically Understanding a Global Audience
20 Feb 2025
Contributed by Lukas
We sit down with Emily Fang, CEO of InFocus Therapeutics, to discuss her global BD career, partnerships in biotech, and the state of RNA-targeting sma...
Ep. 20 Martin Brenner on Intersecting AI and Biology for Obesity
01 Feb 2025
Contributed by Lukas
Martin Brenner is the CEO of iBio, a company advancing antibody therapeutics for obesity using multiple AI engines – but the company started in a ve...
Ep. 19 Kate Beebe DeVarney on Channeling Cancer Challenges into Biotech Innovation
22 Jan 2025
Contributed by Lukas
Kate Beebe Devarney is a neuroscientist and biotech executive focused on bringing relief to cancer patients through Moxie Therapeutics. Listen in as s...
Ep. 18 Jessica Owens on the Art of the Stealth Biotech
21 Dec 2024
Contributed by Lukas
This week we’re joined by Jessica Owens, co-founder and GP at Initiate Ventures, who have just announced their launch of Fund I. A co-founder of GRA...
Ep. 17 John Montgomery on How Branding Unlocks Funding
11 Nov 2024
Contributed by Lukas
John Montgomery of Goodlab joins us for a lively conversation about the visual side of biotech – how a good (or bad!) brand shapes the entire organi...
Ep. 16 Hugh Alsop on Spinning Out Success Across Therapeutic Landscapes
24 Oct 2024
Contributed by Lukas
Join us for a fascinating discussion with Hugh Alsop, CEO of Kinoxis Therapeutics, a spin-out of The University of Sydney. We discuss communicating ha...
Ep. 15 Jonathan Steckbeck on What Biotech Can Learn from Poker
07 Oct 2024
Contributed by Lukas
Jonathan Steckbeck is CEO of Peptilogics, where he is charting a path to therapeutic and commercial success in antimicrobials. Listen in as he describ...
Ep. 14 Jeff Baker and Competitive Advantages in FDA Discussions
19 Sep 2024
Contributed by Lukas
Jeff Baker, biotech veteran and former FDA Deputy Director, describes how the ability to tell a story is a competitive advantage, even in discussions ...
Ep. 13 Simon Goldman on Transforming Hard Science into Global Impact
17 Aug 2024
Contributed by Lukas
Simon Goldman manages the UCL Tech Fund’s life sciences team through Albion VC – he’s especially interested in cell and gene therapies, and shar...
Ep 12 Roy Baynes - Reflections on Cancer Therapy in Celebration of the 10-Year Anniversary of Keytruda
24 Jul 2024
Contributed by Lukas
Roy Baynes M.D., Ph.D, has been instrumental in developing some of the most impactful drugs, including Keytruda. Listen in as he shares his learnings ...
Ep. 11 Chris Hoyt on Pitching and Raising – Perspectives from Tech and Biotech
10 Jul 2024
Contributed by Lukas
Chris Hoyt is a biotech exec focused on advancing cures for neurodegenerative disease, but he comes from a tech background. Listen in as he speaks can...
Ep. 10 Dillan Dinardo on Communicating the Breakthroughs in Psychedelic Medicine
12 Jun 2024
Contributed by Lukas
Dillan Dinardo is a seasoned healthcare investor turned psychedelic medicine leader. Join us as he discusses how psychedelic medicine is the next fron...
Ep. 9 Translating Scientific Innovation from the Lab to the Clinic with John Lewis
31 May 2024
Contributed by Lukas
Explore the entrepreneurial path of John Lewis with us – from Canadian income tax consultant to biotech exec, John has carried a passion for buildin...
Ep. 8 David Lucchino On Solving Serious Problems In Biotech
04 May 2024
Contributed by Lukas
David Lucchino, former Chairman of Mass Bio and CEO of Frequency, has seen every situation from the helm. Join us as we discuss his strategies for com...
Ep. 7 Josh Schimmer: Science And Development Is A Business – A Relationship Business
24 Apr 2024
Contributed by Lukas
Josh Schimmer is the preeminent equity analyst in the biotech industry; he's seen the good, the bad, and the ugly. Join us as we dive deep into his ex...
Ep. 6 Colin Sanford Building a Rewarding Relationship With Your Comms Team
05 Apr 2024
Contributed by Lukas
Colin Sanford is a biotech PR expert, join us as he discusses the importance of on-boarding a comms team early and growing that relationship to ensure...
Ep. 5 Melissa Moore On Why We Need Compelling Stories In Science Communication
25 Mar 2024
Contributed by Lukas
Melissa Moore is a pioneering scientist and an engaging storyteller. Join us as she discusses how compelling storytelling in science communicati...
Ep. 4 Garrett Vygantas On Forging Relationships With Investors Who Build Alongside You
11 Mar 2024
Contributed by Lukas
Join us as we discuss with Garrett Vygantas the essential elements of messaging from a biotech VC investor’s perspective.
Ep. 3 Hartaj Singh Shares His Optimism for Early-Stage Biotech Companies From a Public Market Perspective
27 Feb 2024
Contributed by Lukas
Join us as we discuss with Hartaj Singh the essential elements of messaging in the public biotech arena, and his advice to management teams of early-s...
Ep. 2 Pitch Perfect: Investor Intel Edition with Dan Ferry
16 Feb 2024
Contributed by Lukas
Join us as we discuss with Dan Ferry how he has witnessed the importance of a well-executed communication strategy to drive scientific innovation to t...
Ep.1 The Importance of Storytelling in Early Stage Biotech Fundraising with Dr. Dietrich Stephan
25 Jan 2024
Contributed by Lukas
Join us as we discuss with Dr. Dietrich Stephan how he has used compelling storytelling in his investment pitches to drive scientific innovation to tr...